BioCentury | Oct 22, 2015
Distillery Techniques

Techniques: Zwitterionic polycarboxybetaine (PCB) protein encapsulation for delivery of therapeutic proteins

...Next steps could include testing the delivery platform on other therapeutic proteins. Sanofi markets Elitek rasburicase...
BioCentury | Mar 1, 2010
Company News

sanofi-aventis sales and marketing update

...U.S. rights to the drug from Bayer AG (Xetra:BAY, Leverkusen, Germany). sanofi-aventis also launched Elitek rasburicase...
...tumors likely to result in tumor lysis syndrome and elevated PUA levels. The cost of Elitek...
...in the pediatric population in the U.S. and in Europe, where it is known as Fasturtec...
BioCentury | Nov 2, 2009
Clinical News

Elitek rasburicase regulatory update

...FDA approved an sNDA from sanofi-aventis for Elitek rasburicase to manage plasma uric acid (PUA) levels...
...it is known as Fasturtec. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: Elitek rasburicase ( Fasturtec...
BioCentury | Dec 15, 2008
Clinical News

Elitek: Phase III data

...patients, p=0.06). In patients at high-risk of tumor lysis syndrome, both the rasburicase monotherapy and rasburicase/allopurinol...
...to control PUA was 4.1 hours for patients in each of the rasburicase monotherapy and rasburicase/allopurinol...
...the U.S. for the pediatric population. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: Elitek ( Fasturtec...
BioCentury | Mar 27, 2008
Distillery Therapeutics

This Week in Therapeutics

...At least six companies have compounds in development to treat gout. sanofi-aventis Group markets Fasturtec rasburicase...
BioCentury | Oct 9, 2006
Politics, Policy & Law

Valid biomarkers

...the DakoCytomation EGFR pharmDx test kit Glucose-phosphate dehydrogenase (G6PD) deficiency Elitek rasburicase (sanofi-aventis); Primaquine phosphate Elitek...
BioCentury | Nov 8, 2004
Regulation

CMS listens

...rule Orphan drugs Cover 12 orphan drugs per its definition. Requests that Campath alemtuzumab, Elitek rasburicase...
BioCentury | Apr 6, 2004
Politics & Policy

CMS authorizes pass-through payments

...long-acting risperidone from Alkermes (ALKS) and Johnson & Johnson (JNJ) to treat schizophrenia; and Elitek rasburicase...
...mg of Cubicin; $131.86 per 12.5 mg of Risperdal; and $105.54 per 0.5 mg of Elitek...
BioCentury | Oct 20, 2003
Emerging Company Profile

Phoenix: A better enzyme

...markets Elitek rasburicase to manage plasma uric acid levels in patients with tumor lysis syndrome. Elitek...
BioCentury | Apr 2, 2001
Clinical News

Fasturtec rasburicase regulatory update

...The EU granted marketing approval for Fasturtec to treat and prevent hyperuricemia in patients with hematological...
...the kidneys. Fasturtec is under review in the U.S. Sanofi-Synthelabo SA, Paris, France Product: Fasturtec rasburicase...
Items per page:
1 - 10 of 10